See today's BioWorld
To read the full story, subscribe or sign in.

Denosumab Builds Bone Density, but Infection Concerns Emerge

April 4, 2008
By Donna Young
Amgen Inc.'s experimental osteoporosis drug, denosumab, met all bone mineral density (BMD) endpoints for all skeletal sites in a two-year, 332-patient Phase III study. (BioWorld Today)
BioWorld